Top

Published in:

01-01-2014

Thrombin generation and atherosclerosis

Authors: Jana Kalz, Hugo ten Cate, Henri M. H. Spronk

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2014

Abstract

Atherosclerosis is a major cause of mortality worldwide. The important role inflammation plays in atherosclerosis is evident through the participation of inflammatory cells in the development and progression of the disease. Thrombin is the central protease of the coagulation cascade, involved in the formation of a hemostatic plug to avoid severe bleeding. In addition, thrombin is a key factor in regulating inflammatory processes, signaling through protease activated receptors. We propose that thrombin may be a relevant factor in the atherosclerosis coagulation-inflammation axis. Human histological data show abundant coagulation activity within atherosclerotic lesions with thrombin activity being related to atherosclerotic plaque development and (in)stability. Animal studies establish that the generated thrombin level relates to progression of atherosclerosis, with hypercoagulability producing advanced atherosclerosis in mice with an Apolipoprotein E-deficient (ApoE^−/−) background. Several studies show that administration of direct oral anticoagulants, like dabigatran and rivaroxaban, attenuate atherosclerosis development in ApoE^−/− mice. In this review we explore several mechanisms by which thrombin may operate in modifying the chronic process of atherosclerosis. One of the key elements may be the conversion of thrombin, from a physiological regulator of hemostasis towards an inflammation-mediator under pathophysiological conditions, contributing to a switch in the thrombin-activated protein C (APC) regulation. The ongoing inflammatory activity, indicated by the activation of pro-inflammatory cytokines, neutrophils and neutrophil extracellular traps, drive thrombin generation, while diminishing APC formation. The net result is accelerated pro-inflammatory and pro-thrombotic changes in blood and in the vessel wall. We conclude that these atherogenic influences of thrombin may be clinically relevant in the long term. Further the treatment with long-term anticoagulant therapy deserves further attention as to its potential, vascular side effects.

Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:317–325. doi:10.1038/nature10146 PubMedCrossRef

Ionita MG, van den Borne P, Catanzariti LM et al (2010) High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 30:1842–1848. doi:10.1161/ATVBAHA.110.209296 PubMedCrossRef

Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126. doi:10.1056/NEJM199901143400207 PubMedCrossRef

Lahoute C, Herbin O, Mallat Z, Tedgui A (2011) Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 8:348–358. doi:10.1038/nrcardio.2011.62 PubMedCrossRef

Cybulsky MI, Jongstra-Bilen J (2010) Resident intimal dendritic cells and the initiation of atherosclerosis. Curr Opin Lipidol 21:397–403. doi:10.1097/MOL.0b013e32833ded96 PubMedCrossRef

Hansson GKG (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695. doi:10.1056/NEJMra043430 PubMedCrossRef

Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515–581. doi:10.1152/physrev.00024.2005 PubMedCrossRef

Borissoff JI, Spronk HMH, Heeneman S, ten Cate H (2009) Is thrombin a key player in the “coagulation-atherogenesis” maze? Cardiovasc Res 82:392–403. doi:10.1093/cvr/cvp066 PubMedCrossRef

Weber C, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8:802–815. doi:10.1038/nri2415 PubMedCrossRef

10.

Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3:1800–1814. doi:10.1111/j.1538-7836.2005.01377.x PubMedCrossRef

11.

Kaplan ZS, Jackson SP (2011) The role of platelets in atherothrombosis. Hematol Am Soc Hematol Educ Program 2011:51–61. doi:10.1182/asheducation-2011.1.51 CrossRef

12.

Khrenov AV, Ananyeva NM, Griffin JH, Saenko EL (2002) Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 12:317–324PubMedCrossRef

13.

Borissoff JI, Spronk HMH, ten Cate H (2011) The hemostatic system as a modulator of atherosclerosis. N Engl J Med 364:1746–1760. doi:10.1056/NEJMra1011670 PubMedCrossRef

14.

Hackeng TM, Maurissen LFA, Castoldi E, Rosing J (2009) Regulation of TFPI function by protein S. J Thromb Haemost 7(Suppl 1):165–168. doi:10.1111/j.1538-7836.2009.03363.x PubMedCrossRef

15.

Lane DA, Philippou H, Huntington JA (2005) Directing thrombin. Blood 106:2605–2612. doi:10.1182/blood-2005-04-1710 PubMedCrossRef

16.

Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13:34–45. doi:10.1038/nri3345 PubMedCrossRef

17.

Lipinski S, Bremer L, Lammers T et al (2011) Coagulation and inflammation. Hämostaseologie 31:94–104. doi:10.5482/ha-1134 PubMedCrossRef

18.

Hayden MS, West AP, Ghosh S (2006) NF-kappaB and the immune response. Oncogene 25:6758–6780. doi:10.1038/sj.onc.1209943 PubMedCrossRef

19.

Bajaj MS, Ghosh M, Bajaj SP (2007) Fibronectin-adherent monocytes express tissue factor and tissue factor pathway inhibitor whereas endotoxin-stimulated monocytes primarily express tissue factor: physiologic and pathologic implications. J Thromb Haemost 5:1493–1499. doi:10.1111/j.1538-7836.2007.02604.x PubMedCrossRef

20.

De Jonge E, Dekkers PE, Creasey AA et al (2000) Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95:1124–1129PubMed

21.

O’Brien M (2012) The reciprocal relationship between inflammation and coagulation. Top Companion Animal Med 27:46–52. doi:10.1053/j.tcam.2012.06.003 CrossRef

22.

Antoniak S, Owens AP, Baunacke M et al (2013) PAR-1 contributes to the innate immune response during viral infection. J Clin Invest 123:1310–1322. doi:10.1172/JCI66125 PubMedCentralPubMedCrossRef

23.

Webb JH, Blom AM, Dahlbäck B (2002) Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol 169:2580–2586PubMed

24.

Esmon CT, Xu J, Lupu F (2011) Innate immunity and coagulation. J Thromb Haemost 9(Suppl 1):182–188. doi:10.1111/j.1538-7836.2011.04323.x PubMedCentralPubMedCrossRef

25.

Martinod K, Demers M, Fuchs TA et al (2013) Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci USA 110:8674–8679. doi:10.1073/pnas.1301059110 PubMedCrossRef

26.

Kannemeier C, Shibamiya A, Nakazawa F et al (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 104:6388–6393. doi:10.1073/pnas.0608647104 PubMedCrossRef

27.

Borissoff JI, Joosen IA, Versteylen MO et al (2013) Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol. doi:10.1161/ATVBAHA.113.301627 PubMed

28.

Borissoff JI, ten Cate H (2011) From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism? J Thromb Haemost 9:1791–1794. doi:10.1111/j.1538-7836.2011.04425.x PubMedCrossRef

29.

Fong IW, Chiu B, Viira E et al (1999) De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 67:6048–6055PubMedCentralPubMed

30.

de Kruif MD, van Gorp ECM, Keller TT et al (2005) Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research. Cardiovasc Res 65:317–327. doi:10.1016/j.cardiores.2004.09.031 PubMedCrossRef

31.

Ezzahiri R, Stassen FRM, Kurvers HAJM et al (2003) Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur J Vasc Endovasc Surg 26:88–95PubMedCrossRef

32.

Dechend R, Maass M, Gieffers J et al (1999) Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 100:1369–1373PubMedCrossRef

33.

Kilinc E, Van Oerle R, Borissoff JI et al (2011) Factor XII activation is essential to sustain the procoagulant effects of particulate matter. J Thromb Haemost 9:1359–1367. doi:10.1111/j.1538-7836.2011.04280.x PubMedCrossRef

34.

Hoffmann B, Moebus S, Möhlenkamp S et al (2007) Residential exposure to traffic is associated with coronary atherosclerosis. Circulation 116:489–496. doi:10.1161/CIRCULATIONAHA.107.693622 PubMedCrossRef

35.

Victor VM, Rocha M, Solá E et al (2009) Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 15:2988–3002PubMedCrossRef

36.

Kilinc E, Rudež G, Spronk H (2011) Cardiovascular effects of inhaled ultrafine and nano-sized particles. Wiley, Hoboken

37.

Major CD, Santulli RJ, Derian CK, Andrade-Gordon P (2003) Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol 23:931–939. doi:10.1161/01.ATV.0000070100.47907.26 PubMedCrossRef

38.

Ma L, Dorling A (2012) The roles of thrombin and protease-activated receptors in inflammation. Semin Immunopathol 34:63–72. doi:10.1007/s00281-011-0281-9 PubMedCrossRef

39.

Lin H, Trejo J (2013) Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits β-arrestin-mediated endosomal signaling. J Biol Chem 288:11203–11215. doi:10.1074/jbc.M112.439950 PubMedCrossRef

40.

Seasholtz TM, Majumdar M, Kaplan DD, Brown JH (1999) Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 84:1186–1193PubMedCrossRef

41.

Patterson C, Stouffer GA, Madamanchi N, Runge MS (2001) New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res 88:987–997PubMedCrossRef

42.

McCoy KL, Gyoneva S, Vellano CP et al (2012) Protease-activated receptor 1 (PAR1) coupling to G(q/11) but not to G(i/o) or G(12/13) is mediated by discrete amino acids within the receptor second intracellular loop. Cell Signal 24:1351–1360. doi:10.1016/j.cellsig.2012.01.011 PubMedCentralPubMedCrossRef

43.

Hamilton JR, Cornelissen I, Mountford JK, Coughlin SR (2009) Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE^−/− mice. Atherosclerosis 205:427–432. doi:10.1016/j.atherosclerosis.2009.01.018 PubMedCentralPubMedCrossRef

44.

Chen D, Dorling A (2009) Critical roles for thrombin in acute and chronic inflammation. J Thromb Haemost 7(Suppl 1):122–126. doi:10.1111/j.1538-7836.2009.03413.x PubMedCrossRef

45.

Feistritzer C, Lenta R, Riewald M (2005) Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost 3:2798–2805. doi:10.1111/j.1538-7836.2005.01610.x PubMedCrossRef

46.

Esmon CT (2012) Protein C anticoagulant system—anti-inflammatory effects. Semin Immunopathol 34:127–132. doi:10.1007/s00281-011-0284-6 PubMedCentralPubMedCrossRef

47.

Bouwens EAM, Stavenuiter F, Mosnier LO (2013) Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 11(Suppl 1):242–253. doi:10.1111/jth.12247 PubMedCrossRef

48.

Matsumoto K, Yano Y, Gabazza EC et al (2007) Inverse correlation between activated protein C generation and carotid atherosclerosis in Type 2 diabetic patients. Diabet Med 24:1322–1328. doi:10.1111/j.1464-5491.2007.02289.x PubMedCrossRef

49.

Wilcox JN, Noguchi S, Casanova JR, Rasmussen ME (2001) Extrahepatic synthesis of FVII in human atheroma and smooth muscle cells in vitro. Ann N Y Acad Sci 947:433–438PubMedCrossRef

50.

Borissoff JI, Heeneman S, Kilinc E et al (2010) Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 122:821–830. doi:10.1161/CIRCULATIONAHA.109.907121 PubMedCrossRef

51.

Loeffen R, Spronk HMH, ten Cate H (2012) The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost 10:1207–1216. doi:10.1111/j.1538-7836.2012.04782.x PubMedCrossRef

52.

Borissoff JI, Joosen IA, Versteylen MO et al (2012) Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. JCMG 5:1201–1210. doi:10.1016/j.jcmg.2012.01.023

53.

Konings J, Govers-Riemslag JWP, Philippou H et al (2011) Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 118:3942–3951. doi:10.1182/blood-2011-03-339572 PubMedCrossRef

54.

Nelken NA, Soifer SJ, O’Keefe J et al (1992) Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90:1614–1621. doi:10.1172/JCI116031 PubMedCentralPubMedCrossRef

55.

Colotta F, Sciacca FL, Sironi M et al (1994) Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 144:975–985PubMed

56.

Gu L, Okada Y, Clinton SK et al (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2:275–281PubMedCrossRef

57.

Boring L, Gosling J, Cleary M, Charo IF (1998) Decreased lesion formation in CCR2^−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894–897. doi:10.1038/29788 PubMedCrossRef

58.

Minami T, Sugiyama A, Wu S-Q et al (2004) Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 24:41–53. doi:10.1161/01.ATV.0000099880.09014.7D PubMedCrossRef

59.

Naldini A, Carney DH, Pucci A et al (2000) Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1. Gen Pharmacol 35:255–259PubMedCrossRef

60.

Shpacovitch VM, Brzoska T, Buddenkotte J et al (2002) Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol 118:380–385. doi:10.1046/j.0022-202x.2001.01658.x PubMedCrossRef

61.

Dabbagh K, Laurent GJ, McAnulty RJ, Chambers RC (1998) Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism. Thromb Haemost 79:405–409PubMed

62.

Kastl SP, Speidl WS, Katsaros KM et al (2009) Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood 114:2812–2818. doi:10.1182/blood-2009-01-200915 PubMedCrossRef

63.

Levi M, van der Poll T (2008) The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 34:459–468. doi:10.1055/s-0028-1092876 PubMedCrossRef

64.

Borissoff JI, Otten JJT, Heeneman S et al (2013) Genetic and pharmacological modifications of thrombin formation in apolipoprotein E-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS ONE 8:e55784. doi:10.1371/journal.pone.0055784.s008 PubMedCentralPubMedCrossRef

65.

Khallou-Laschet J, Caligiuri G, Tupin E et al (2005) Role of the intrinsic coagulation pathway in atherogenesis assessed in hemophilic apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 25:e123–e126. doi:10.1161/01.ATV.0000171995.22284.9a PubMedCrossRef

66.

Tilley RER, Pedersen BB, Pawlinski RR et al (2006) Atherosclerosis in mice is not affected by a reduction in tissue factor expression. Arterioscler Thromb Vasc Biol 26:555–562. doi:10.1161/01.ATV.0000202028.62414.3c PubMedCrossRef

67.

Vicente CP, He L, Tollefsen DM (2007) Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood 110:4261–4267. doi:10.1182/blood-2007-04-086611 PubMedCrossRef

68.

Westrick RJ, Bodary PF, Xu Z et al (2001) Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 103:3044–3046PubMedCrossRef

69.

Bea F, Kreuzer J, Preusch M et al (2006) Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 26:2787–2792. doi:10.1161/01.ATV.0000246797.05781.ad PubMedCrossRef

70.

Burghaus R, Coboeken K, Gaub T et al (2011) Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS ONE 6:e17626. doi:10.1371/journal.pone.0017626 PubMedCentralPubMedCrossRef

71.

Zhou Q, Bea F, Preusch M et al (2011) Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011:432080. doi:10.1155/2011/432080 PubMedCentralPubMedCrossRef

72.

Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151. doi:10.1056/NEJMoa0905561 PubMedCrossRef

73.

Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9–19. doi:10.1056/NEJMoa1112277 PubMedCrossRef

Title: Thrombin generation and atherosclerosis
Authors: Jana Kalz
Hugo ten Cate
Henri M. H. Spronk
Publication date: 01-01-2014
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 1/2014
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-013-1026-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

New paradigms in thrombosis: novel mediators and biomarkers platelet RNA transfer

Small cells, big effects: the role of platelets in transplant vasculopathy

Modeling thrombin generation: plasma composition based approach

Targeting the host hemostatic system function in bacterial infection for antimicrobial therapies

Novel mediators and biomarkers of thrombosis

A novel role for bioactive lipids in stem cell mobilization during cardiac ischemia

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage